2000-2003

2003

• Krämer, S. D., Wunderli-Allenspach, H. (2003) No entry for TAT(44-57) into liposomes and intact MDCK cells: novel approach to study membrane permeation of cell-penetrating peptides. Biochim. Biophys. Acta 1609, 161-169.

2002

• Krämer, S. D., Schutz, Y. B, Wunderli-Allenspach, H, Abbott, N. J., Begley, D. J. (2002) Lipids in blood-brain barrier models in vitro II: Influence of glial cells on lipid classes and lipid fatty acids. In Vitro Cell. Dev. Biol.-Animal 38, 566-71.
  
  
• Niesner, U., Halin C., Lozzi, L., Günthert, M., Neri, P., Wunderli-Allenspach, H., Zardi, L., Neri, D. (2002) Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjugate Chem., 13, 729-736.
  
  
• Pietzonka, P., Rothen-Rutishauser, B., Langguth P., Wunderli-Allenspach, H., Walter, E., Merkle, H. P. (2002) Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to Caco-2 monolayers mimics particle uptake. Pharm. Res. 19, 595-601.
  
  
• Riesen, F. K., Rothen-Rutishauser, B., Wunderli-Allenspach, H. (2002) A ZO1-GFP fusion protein to study the dynamics of tight junctions in living cells. Histochem. Cell Biol. 117, 307-315.
  
  
• Rothen-Rutishauser, B., Riesen, F. K., Braun, A., Günthert, M., Wunderli-Allenspach, H. (2002) Dynamics of tight and adherens junctions under EGTA treatment. J. Memb. Biol. 188, 151-162.
  
  
• Schwarzwald, C. C., Feige, K., Wunderli-Allenspach, H., Braun, U. (2002) Comparison of pharmacokinetic variables for two low-molecular-weight heparins after subcutaneous administration of a single dose to horses. Am. J. Vet. Res. 63, 868-873.
  
  
• Suda, K., Rothen-Ruthishauser, B., Günthert, M., Wunderli-Allenspach, H. (2002) Response to the report by Drexler et al. In Vitro Cell. Dev. Biol.-Animal 38, 187

2001

• Wunderli-Allenspach, H. (2001) Methodologies in cell culture. In: Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies. Eds. B. Testa, H. van de Waterbeemd, G. Folkers and R. Guy. Wiley-VCH, Weinheim.
  
  
• Beyer, U., Rothen-Rutishauser, B., Unger, C., Wunderli-Allenspach, H., and Kratz, F. (2001) Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy. Pharm. Res., 18, 29-38.
  
  
• Langer, M., Kratz, F., Rothen-Rutishauser, B., Wunderli-Allenspach, H., and Beck-Sickinger, A. G. (2001) Novel peptide conjugates for tumor-specific chemotherapy. J. Med. Chem., 44, 1341-1348.
  
  
• Krämer, S. D., and Wunderli-Allenspach, H. (2001) Physicochemical properties in pharmacokinetic lead optimization. Farmaco, 56, 145-148.
  
  
• Suda, K., Rothen-Rutishauser, B., Günthert, M., and Wunderli-Allenspach, H. (2001) Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: Endothelial versus epithelial features. In Vitro Cell. Dev. Biol.-Animal, 37, 505-514.
  
  
• Thiele, L., Rothen-Rutishauser, B., Jilek, S., Wunderli-Allenspach, H., Merkle, H. P., and Walter, E. (2001) Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J. Control. Release, 76, 59-71.

2000

• Beermann, C., Wunderli-Allenspach, H., Groscurth, P., and Filgueira, L. (2000) Lipoproteins from Borrelia burgdorferi applied in liposomes and presented by dendritic cells induce CD8+ T-lymphocytes in vitro. Cell. Immunol. 201, 124-131.
  
  
• Cattaneo-Pangrazzi, R. M. C., Schott, H., Wunderli-Allenspach, H., Rothen-Rutishauser, B., Günthert, M., and Schwendener, R. A. (2000) Cell cycle arrest and p53-independent induction of apoptosis by the new anticancer drugs 5-FdUrd-P-FdCydOct and dCydpam-P-FdUrd in DU-145 human prostate cancer cells. J. Cancer Res. Clin. Oncol. 126, 247-256.
  
  
• Cattaneo-Pangrazzi, R. M. C., Schott, H., Wunderli-Allenspach, H., Derighetti, M. I., and Schwendener, R. A. (2000) Induction of cell cycle-dependent cytotoxicity and apoptosis by new heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine in PC-3 human prostate cancer cells. Biochem. Pharmacol., 60, 1887-1896.
  
  
• Friebe, M., Suda, K., Spies, H., Syhre, R., Berger, R., Johannsen, B, Efstratios, C., Krämer, S. D., Wunderli-Allenspach H. (2000) Permeation studies in vitro and in vivo of potential radiopharmaceuticals with affinity to neuro receptors. Pharm. Res. 17, 754-760.
  
  
• Hämmerle, S. P., Rothen-Rutishauser, B., Krämer, S. D., Günthert, M., Wunderli-Allenspach, H. (2000) P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. Eur. J. Pharm. Sci., 12, 69-77.
  
  
• Rothen-Rutishauser, B., Braun, A., Günthert, M., Wunderli-Allenspach, H. (2000) Formation of multilayers in the Caco-2 cell culture model: A confocal laser scanning microscopy study. Pharm. Res. 17, 460-465.
  
  
• Braun, A., Hämmerle, S. P., Suda, K., Rothen-Rutishauser, B., Günthert, M., Krämer, S. D., Wunderli-Allenspach, H. (2000) Cell cultures as tools in biopharmacy. Eur. J. Pharm. Sci., 11 Suppl. 2, S51-S60.

• Fabry, M., Langer, M., Rothen-Rutishauser, B., Wunderli-Allenspach, H., Höcker, H., Beck-Sickinger, A. (2000) Monitoring of the internalization of neuropeptide Y on neuroblastoma cell line SK-N-MC. Eur. J. Biochem. 267, 5631-5637.